Bosulif (Bosutinib)

BOSULIF (Bosutinib)

BOSULIF

Bosutinib

100 mg/400 mg/500 mg, and Capsules 50 mg/100 mg

Pfizer

Medical Use

Bosulif (bosutinib) is a kinase inhibitor used to treat chronic myelogenous leukemia (CML) in both adults and children aged 1 year and older. It is prescribed for patients in the chronic phase of Philadelphia chromosome-positive (Ph+) CML, whether they are newly diagnosed or have not responded well to previous treatments. Additionally, Bosulif is used in adults with advanced stages of Ph+ CML, such as the accelerated or blast phase, when they have shown resistance or intolerance to prior therapies.

Recommended Dosage:

  • -Take Bosulif once a day with food.
  • -Swallow the tablets whole—do not cut, crush, break, or chew them.
  • -Continue using Bosulif until your doctor advises stopping due to disease progression or side effects.

Capsules:

  • -Swallow capsules whole.
  • -If you have trouble swallowing capsules, you can open them and mix the contents with applesauce or yogurt. However, this mixture should not replace a full meal.

Missed Dose:

  • -If you miss a dose and more than 12 hours have passed, skip that dose and take your next scheduled dose at the usual time the following day.

Dosage Guidelines:

  • -Adults with Newly-Diagnosed CP Ph+ CML: 400 mg orally once daily with food.
  • -Adults with CP, AP, or BP Ph+ CML with Resistance or Intolerance to Prior Therapy: 500 mg orally once daily with food.
  • -Pediatric Patients with Newly-Diagnosed CP Ph+ CML or with CP Ph+ CML with Resistance or Intolerance to Prior Therapy: 300 mg/m² orally once daily with food for newly diagnosed cases, and 400 mg/m² orally once daily with food for resistant or intolerant cases.